Advanced Sleep Melatonin

Name: Advanced Sleep Melatonin

What should I discuss with my health care provider before taking Advanced Sleep Melatonin (melatonin)?

You should not use melatonin if you are allergic to it.

Before using melatonin, talk to your healthcare provider. You may not be able to use melatonin if you have certain medical conditions, especially:

  • diabetes;

  • depression;

  • a bleeding or blood clotting disorder such as hemophilia;

  • high or low blood pressure;

  • epilepsy or other seizure disorder; or

  • if you are using any medicine to prevent organ transplant rejection.

It is not known whether melatonin will harm an unborn baby. Do not use this product without medical advice if you are pregnant.

High doses of melatonin may affect ovulation, making it difficult for you to get pregnant.

It is not known whether melatonin passes into breast milk or if it could harm a nursing baby. Do not use this product without medical advice if you are breast-feeding a baby.

Do not give any herbal/health supplement to a child without medical advice.

Is Melatonin a Hormone?

Melatonin is a natural hormone when produced in the body (the endogenous hormone). Melatonin is not a vitamin. Melatonin supplements (exogenous hormone) are made synthetically and all products and strengths on the U.S. market are available without a prescription at the pharmacy, nutrition stores, and other retail shops.

Melatonin is most commonly used to:

  • help decrease jet lag
  • adjust sleep cycles in the blind (non 24-Hour Sleep Wake Disorder, or Non-24)
  • treat shift-work sleep disorders in people with alternating work schedules
  • for general insomnias

How Does Melatonin Work?

Natural melatonin is a highly lipid soluble hormone produced in the pineal gland in the brain. It is synthesized from the amino acid tryptophan and then released into the blood and cerebrospinal fluid, crossing the blood-brain barrier. It sends messages to the melatonin receptor agonist in the brain and other areas of the body to help control the sleep and wake cycles.

Does melatonin help you sleep? When taken as supplement, the function of melatonin is to mimic the effects of the natural hormone. Drowsiness generally occurs within 30 minutes after taking melatonin. However, taking melatonin right before bed may not be the best strategy for all sleep disorders. Ask your doctor about the best method of dosing melatonin. Melatonin does not work for everyone.

Melatonin for Jet Lag

  • Eastbound: If you are traveling east, say from the US to Europe, take melatonin after dark, 30 minutes before bedtime in the new time zone or if you are on the plane. Then take it for the next 4 nights in the new time zone, after dark, 30 minutes before bedtime. If drowsy the day after melatonin use, try a lower dose.
  • Westbound: If you are heading west, for example, from the US to Australia, a dose is not needed for your first travel night, but you then may take it for the next 4 nights in the new time zone, after dark, 30 minutes before bedtime. Melatonin may not always be needed for westbound travel.

Given enough time (usually 3 to 5 days), jet lag will usually resolve on its own, but this is not always optimal when traveling.


Information regarding safety and efficacy in pregnancy and lactation is lacking.


1. Srinivasan V, Pandi-Perumal SR, Trahkt I, et al. Melatonin and melatonergic drugs on sleep: possible mechanisms of action. Int J Neurosci . 2009;119(6):821-846.
2. Windholz M, ed. Merck Index . 11th ed. Rahway, NJ: Merck and Co; 1989.
3. Bowman WC, Rand MJ. Textbook of Pharmacology . 2nd ed. St. Louis: Blackwell Scientific Publications; 1980.
4. Reiter RJ, Tan DX, Sainz RM, Mayo JC, Lopez-Burillo S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol . 2002;54(10):1299-1321.
5. Wehr TA. Photoperiodism in humans and other primates: evidence and implications. J Biol Rhythms . 2001;16(4):348-364.
6. Webb SM, Puig-Domingo M. Role of melatonin in health and disease. Clin Endocrinol (Oxf) . 1995;42(3):221-234.
7. Generali JA. Keeping Up: Melatonin. Drug Newsletter . 1996;15:3.
8. Cowley G. Melatonin. Newsweek . 1995;Aug 7:46.
9. Mulder H, Nagorny CL, Lyssenko V, Groop L. Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene. Diabetologia . 2009;52(7):1240-1249.
10. Arendt J. Melatonin. Clin Endocrinol (Oxf) . 1988;29(2):205-229.
11. Borbély AA. Commentary on the articles by Arendt, Weaver, Mahle et al., and Guardiola-Lemaitre. J Biol Rhythms . 1997;12(6):707-708.
12. Aldhous M, Franey C, Wright J, Arendt J. Plasma concentrations of melatonin in man following oral absorption of different preparations. Br J Clin Pharmacol . 1985;19(4):517-521.
13. Sack RL, Lewy AJ, Blood ML, Stevenson J, Keith LD. Melatonin administration to blind people: phase advances and entrainment. J Biol Rhythms . 1991;6(3):249-261.
14. Reiter RJ, Melchiorri D, Sewerynek E, et al. A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res . 1995;18(1):1-11.
15. Poeggeler B, Saarela S, Reiter RJ, et al. Melatonina highly potent endogenous radical scavenger and electron donor: new aspects of the oxidation chemistry of this indole accessed in vitro. Ann N Y Acad Sci . 1994;738:419-420.
16. Löffler M. Melatonin as antioxidantuse or misuse? Exp Clin Endocrinol Diabetes . 1996;104(4):308-310.
17. Cagnacci A, Soldani R, Yen SS. Hypothermic effect of melatonin and nocturnal core body temperature decline are reduced in aged women. J Appl Physiol . 1995;78(1):314-317.
18. Morgan PJ, Mercer JG. Control of seasonality by melatonin. Proc Nutr Soc . 1994;53(3):483-493.
19. Partonen T. Involvement of melatonin and serotonin in winter depression. Med Hypotheses . 1994;43(3):165-166.
20. Cos S, Blask DE. Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. J Pineal Res . 1994;17(1):25-32.
21. Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer . 1996;32A(8):1340-1343.
22. Leone M. Melatonin and primary headache. Cephalalgia . 1994;14(3):183.
23. Leone M, D'Amico D, Moschiano F, Fraschini F, Bussone G. Melatonin versus placebo in the prophylaxis of cluster headache: a double-blind pilot study with parallel groups. Cephalalgia . 1996;16(7):494-496.
24. Poon AM, Liu ZM, Pang CS, Brown GM, Pang SF. Evidence for a direct action of melatonin on the immune system. Biol Signals . 1994;3(2):107-117.
25. Maestroni GJ. The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs . 2001 Mar;10(3):467-476.
26. Morrey KM, McLachlan JA, Serkin CD, Bakouche O. Activation of human monocytes by the pineal hormone melatonin. J Immunol . 1994;153(6):2671-2680.
27. Bubenik GA, Pang SF. The role of serotonin and melatonin in gastrointestinal physiology: ontogeny, regulation of food intake, and mutual serotonin-melatonin feedback. J Pineal Res . 1994;16(2):91-99.
28. Saarela S, Reiter RJ. Function of melatonin in thermoregulatory processes. Life Sci . 1994;54(5):295-311.
29. Pang CS, Brown GM, Tang PL, Cheng KM, Pang SF. 2-[125I]iodomelatonin binding sites in the lung and heart: a link between the photoperiodic signal, melatonin, and the cardiopulmonary system. Biol Signals . 1993;2(4):228-236.
30. Cagnacci A, Arangino S, Angiolucci M, Maschio E, Longu G, Melis GB. Potentially beneficial cardiovascular effects of melatonin administration in women. J Pineal Res . 1997;22(1):16-19.
31. Cagnacci A, Arangino S, Angiolucci M, et al. Effect of exogenous melatonin on vascular reactivity and nitric oxide in postmenopausal women: role of hormone replacement therapy. Clin Endocrinol (Oxf) . 2001;54(2):261-266.
32. Pittalis S, Lissoni P, Giani L, et al. Effect of a chronic therapy with the pineal hormone melatonin on cholesterol levels in idiopathic hypercholesterolemic patients. Recenti Prog Med . 1997;88(9):401-402.
33. Jan JE, Connolly MB, Hamilton D, Freeman RD, Laudon M. Melatonin treatment of non-epileptic myoclonus in children. Dev Med Child Neurol . 1999;41(4):255-259.
34. Cavallo A. Melatonin and human puberty: current perspectives. J Pineal Res . 1993;15(3):115-121.
35. Rosenberg SI, Silverstein H, Rowan PT, Olds MJ. Effect of melatonin on tinnitus. Laryngoscope . 1998;108(3):305-310.
36. Pevet P. Present and future of melatonin in human and animal reproduction functions [in French]. Contracept Fertil Sex . 1993;21(10):727-732.
37. Dawson D, Encel N. Melatonin and sleep in humans. J Pineal Res . 1993;15(1):1-12.
38. Naguib M, Samarkandi AH. The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: a double-blinded, placebo-controlled study. Anesth Analg . 2000;91(2):473-479.
39. Carneiro RC, Pereira EP, Cipolla-Neto J, Markus RP. Age-related changes in melatonin modulation of sympathetic neurotransmission. J Pharmacol Exp Ther . 1993;266(3):1536-1540.
40. Weissbluth L, Weissbluth M. The photo-biochemical basis of infant colic: pineal intracellular calcium concentrations controlled by light, melatonin, and serotonin. Med Hypotheses . 1993;40(3):158-164.
41. Sandyk R, Tsagas N, Anninos PA. Melatonin as a proconvulsive hormone in humans. Int J Neurosci . 1992;63(1-2):125-135.
42. Armstrong SM, Redman JR. Melatonin: a chronobiotic with anti-aging properties? Med Hypotheses . 1991;34(4):300-309.
43. Reiter RJ. Pineal function during aging: attenuation of the melatonin rhythm and its neurobiological consequences. Acta Neurobiol Exp (Wars) . 1994;54(5):31-39.
44. Shamir E, Barak Y, Plopsky I, Zisapel N, Elizur A, Weizman A. Is melatonin treatment effective for tardive dyskinesia? J Clin Psychiatry . 2000;61(8):556-558.
45. Leibenluft E, Feldman-Naim S, Turner EH, Wehr TA, Rosenthal NE. Effects of exogenous melatonin administration and withdrawal in five patients with rapid-cycling bipolar disorder. J Clin Psychiatry . 1997;58(9):383-388.
46. Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry . 1998;155(8):1119-1121.
47. Levy SE, Hyman SL. Complementary and alternative medicine treatments for children with autism spectrum disorders. Child Adolesc Psychiatr Clin N Am . 2008;17(4):803-820.
48. Giannotti F, Cortesi F, Cerquiglini A, Bernabei P. An open-label study of controlled-release melatonin in treatment of sleep disorders in children with autism. J Autism Dev Disord . 2006;36(6):741-752.
49. Andersen IM, Kaczmarska J, McGrew SG, Malow BA. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol . 2008;23(5):482-485.
50. Melke J, Goubran Botros H, Chaste P, et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry . 2008;13(1):90-98.
51. Wheeler B, Taylor B, Simonsen K, Reith DM. Melatonin treatment in Smith Magenis syndrome. Sleep . 2005;28(12):1609-1610.
52. Weiss MD, Wasdell MB, Bomben MM, Rea KJ, Freeman RD. Sleep hygiene and melatonin treatment for children and adolescents with ADHD and initial insomnia. J Am Acad Child Adolesc Psychiatry . 2006;45(5):512-519.
53. Tzischinsky O, Pal I, Epstein R, Dagan Y, Lavie P. The importance of timing in melatonin administration in a blind man. J Pineal Res . 1992;12(3):105-108.
54. Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int . 1992;9(5):380-392.
55. Lino A, Silvy S, Condorelli L, Rusconi AC. Melatonin and jet lag: treatment schedule. Biol Psychiatry . 1993;34(8):587.
56. Petrie K, Dawson AG, Thompson L, Brook R. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. Biol Psychiatry . 1993;33(7):526-530.
57. Claustrat B, Brun J, David M, Sassolas G, Chazot G. Melatonin and jet lag: confirmatory result using a simplified protocol. Biol Psychiatry . 1992;32(8):705-711.
58. Arendt J. Jet-lag and shift work: (2). Therapeutic use of melatonin. J R Soc Med . 1999;92(8):402-405.
59. Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology (Berl) . 1990;100(2):222-226.
60. MacFarlane JG, Cleghorn JM, Brown GM, Streiner DL. The effects of exogenous melatonin on the total sleep time and daytime alertness of chronic insomniacs: a preliminary study. Biol Psychiatry . 1991;30(4):371-376.
61. Dollins AB, Lynch HJ, Wurtman RJ, et al. Effect of pharmacological daytime doses of melatonin on human mood and performance. Psychopharmacology (Berl) . 1993;112(4):490-496.
62. James SP, Sack DA, Rosenthal NE, Mendelsohn WB. Melatonin administration in insomnia. Neuropsychopharmacology . 1989;3(1):19-23.
63. Tzischinsky O, Lavie P. Melatonin possesses time-dependent hypnotic effects. Sleep . 1994 Oct;17(7):638-645.
64. Nave R, Peled R, Lavie P. Melatonin improves evening napping. Eur J Pharmacol . 1995;275(2):213-216.
65. Zhdanova IV, Wurtman RJ, Lynch HJ, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther . 1995;57(5):552-558.
66. Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet . 1995;346(8974):541-544.
67. Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep . 1995;18(7):598-603.
68. Kayumov L, Brown G, Jindal R, Buttoo K, Shapiro CM. A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom Med . 2001;63(1):40-48.
69. Andrade C, Srihari BS, Reddy KP, Chandramma L. Melatonin in medically ill patients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry . 2001;62(1):41-45.
70. Buscemi N, Vandermeer B, Hooton N, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ . 2006;332(7538):385-393.
71. Jan JE, Espezel H, Appleton RE. The treatment of sleep disorders with melatonin. Dev Med Child Neurol . 1994;36(2):97-107.
72. Smits MG, Nagtegaal EE, van der Heijden J, Coenen AM, Kerkhof GA. Melatonin for chronic sleep onset insomnia in children: a randomized placebo-controlled trial. J Child Neurol . 2001 Feb;16(2):86-92.
73. Jan JE, Hamilton D, Seward N, Fast DK, Freeman RD, Laudon M. Clinical trials of controlled-release melatonin in children with sleep-wake cycle disorders. J Pineal Res . 2000;29(1):34-39.
74. Van der Heijden KB, Smits MG, Van Someren EJ, Ridderinkhof KR, Gunning WB. Effect of melatonin on sleep, behavior, and cognition in ADHD and chronic sleep-onset insomnia. J Am Acad Child Adolesc Psychiatry . 2007;46(2):233-241.
75. Megwalu UC, Finnell JE, Piccirillo JF. The effects of melatonin on tinnitus and sleep. Otolaryngol Head Neck Surg . 2006;134(2):210-213.
76. Citera G, Arias MA, Maldonado-Cocco JA, et al. The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol . 2000;19(1):9-13.
77. Acuna-Castroviejo D, Escames G, Reiter RJ. Melatonin therapy in fibromyalgia. J Pineal Res . 2006;40(1):98-99.
78. Todisco M. Effectiveness of a treatment based on melatonin in five patients with systemic sclerosis. Am J Ther . 2006;13(1):84-87.
79. Sauer LA, Dauchy RT, Blask DE. Polyunsaturated fatty acids, melatonin, and cancer prevention. Biochem Pharmacol . 2001;61(12):1455-1462.
80. Jan JE, Tai J, Hahn G, Rothstein RR. Melatonin replacement therapy in a child with a pineal tumor. J Child Neurol . 2001;16(2):139-140.
81. Lissoni P, Barni S, Cattaneo G, et al. Clinical results with the pineal hormone melatonin in advanced cancer resistant to standard antitumor therapies. Oncology . 1991;48(6):448-450.
82. Zumoff B. Hormonal profiles in women with breast cancer. Obstet Gynecol Clin North Am . 1994;21(4):751-772.
83. Lissoni P, Barni S, Tancini G, et al. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors. Oncology . 1995;52(2):163-166.
84. Lissoni P, Barni S, Brivio F, et al. A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia. Oncology . 1995;52(5):360-362.
85. Barni S, Lissoni P, Cazzaniga M, et al. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folate. Oncology . 1995;52(3):243-245.
86. Siu AW, Maldonado M, Sanchez-Hidalgo M, Tan DX, Reiter RJ. Protective effects of melatonin in experimental free radical-related ocular diseases. J Pineal Res . 2006;40(2):101-109.
87. Ismail SA, Mowafi HA. Melatonin provides anxiolysis, enhances analgesia, decreases intraocular pressure, and promotes better operating conditions during cataract surgery under topical anesthesia. Anesth Analg . 2009;108(4):1146-1151.
88. Werbach MR. Melatonin for the treatment of gastroesophageal reflux disease. Altern Ther Health Med . 2008;14(4):54-58.
89. Song GH, Leng PH, Gwee KA, Moochhala SM, Ho KY. Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study. Gut . 2005;54(10):1402-1407.
90. Lu WZ, Gwee KA, Moochhalla S, Ho KY. Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther . 2005;22(10):927-934.
91. Klupínska G, Poplawski T, Drzewoski J, et al. Therapeutic effect of melatonin in patients with functional dyspepsia. J Clin Gastroenterol . 2007;41(3):270-274.
92. Kedziora-Kornatowska K, Szewczyk-Golec K, Kozakiewicz M, et al. Melatonin improves oxidative stress parameters measured in the blood of elderly type 2 diabetic patients. J Pineal Res . 2009;46(3):333-337.
93. Voordouw BC, Euser R, Verdonk RE, et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab . 1992;74(1):108-117.
94. Dreher F, Gabard B, Schwindt DA, Maibach HI. Topical melatonin in combination with vitamins E and C protects skin from ultraviolet-induced erythema: a human study in vivo. Br J Dermatol . 1998;139(2):332-339.
95. Maldonado MD, Murillo-Cabezas F, Calvo JR, et al. Melatonin as pharmacologic support in burn patients: a proposed solution to thermal injury-related lymphocytopenia and oxidative damage. Crit Care Med . 2007;35(4):1177-1185.
96. Saeidi M, Sobhani R, Movahedi M, Alsaeidi S, Samani RE. Effect of melatonin in the prevention of postoperative pericardial adhesion formation. Interact Cardiovasc Thorac Surg . 2009;9(1):26-28.
97. Härtter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol . 2003;56(6):679-682.
98. Facciolá G, Hidestrand M, von Bahr C, Tybring G. Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol . 2001;56(12):881-888.
99. Härtter S, Grözinger M, Weigmann H, Röschke J, Hiemke C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther . 2000;67(1):1-6.
100. Lusardi P, Piazza E, Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. Br J Clin Pharmacol . 2000;49(5):423-427.
101. Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev . 2002;(2):CD00152.
102. Seabra ML, Bignotto M, Pinto LR Jr, Tufik S. Randomized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res . 2000;29(4):193-200.
103. Bardazzi F, Placucci F, Neri I, D'Antuono A, Patrizi A. Fixed drug eruption due to melatonin. Acta Derm Venereol . 1998;78(1):69-70.
104. Force RW, Hansen L, Bedell M. Psychotic episode after melatonin. Ann Pharmacother . 1997;31(11):1408.
105. De Bleecker JL, Lamont BH, Verstraete AG, Schelfhout VJ. Melatonin and painful gynecomastia. Neurology . 1999;53(2):435-436.
106. Hong YG, Riegler JL. Is melatonin associated with the development of autoimmune hepatitis? J Clin Gastroenterol . 1997;25(1):376-378.
107. Graw P, Werth E, Kräuchi K, Gutzwiller F, Cajochen C, Wirz-Justice A. Early morning melatonin administration impairs psychomotor vigilance. Behav Brain Res . 2001;121(1-2):167-172.
108. Sheldon SH. Pro-convulsant effects of oral melatonin in neurologically disabled children. Lancet . 1998;351(9111):1254.

Copyright © 2009 Wolters Kluwer Health